← Leaderboards
Sridhar Nimmagadda
Johns Hopkins University
$5,268,119
Attributed
$6,575,691
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,575,691 · 3
By mechanism
R01$6,575,691 · 3
Top collaborators
- Steven P Rowe4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Kristine Glunde$12,806,818
- Martin G Pomper$38,517,075
- Christine A Iacobuzio-Donahue$15,673,191
- Venu Raman$6,874,952
- Zhaoli Sun$13,175,173
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorPerformanceRadiotracerImageIn VivoAffinityPositron-Emission TomographyMalignant NeoplasmsImaging AgentBaseImmunohistochemistryDrug KineticsImmune CheckpointImmunosuppressionMultidisciplinaryNon-Small-Cell Lung CarcinomaLesionCancer ImmunotherapyCheckpoint TherapyHumanized MouseClinical TranslationContrast ImagingBiologicalCharacteristics
Grant awards (14)
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$693,779
R01 · FY2025 · CA · contact PI
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$635,583
R01 · FY2024 · CA · contact PI
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$660,982
R01 · FY2023 · CA · contact PI
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$624,800
R01 · FY2022 · CA · contact PI
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor$448,389
R01 · FY2022 · CA · contact PI
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor$457,540
R01 · FY2021 · CA · contact PI
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor$457,540
R01 · FY2020 · CA · contact PI
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor$443,812
R01 · FY2019 · CA · contact PI
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor$520,780
R01 · FY2018 · CA · contact PI
Imaging and targeting metastatic disease$336,150
R01 · FY2016 · CA · contact PI
Imaging and targeting metastatic disease$336,150
R01 · FY2015 · CA · contact PI
Imaging and targeting metastatic disease$326,066
R01 · FY2014 · CA · contact PI
Imaging and targeting metastatic disease$315,981
R01 · FY2013 · CA · contact PI
Imaging and targeting metastatic disease$318,139
R01 · FY2012 · CA · contact PI